Hairy Cell Leukemia Presenting with a Lytic Bone Lesion

Pemmaraju, N.; Gill, Javed; Krause, John R.

doi:10.1080/08998280.2015.11929191

Cited by 4 publications

(7 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinically significant extranodal involvement by HCL is rare, and may occur at presentation or in patients with long‐standing disease . Affected sites include lytic bone lesions, central nervous system, skin, breast and salivary gland . Autopsy studies have revealed leukaemic infiltration in multiple organs, although typically without contribution to morbidity or mortality …”

Section: Discussionmentioning

confidence: 99%

Morphological and immunophenotypical features of hairy cell leukaemia involving lymph nodes and extranodal tissues

et al. 2017

View full text Add to dashboard Cite

Although uncommon, HCL should be considered in the differential diagnosis of small B cell neoplasms involving nodal/extranodal sites, given the therapeutic implications. In particular, recent discoveries including detection of the BRAF mutation in nearly all cases of HCL and the availability of an antibody to CD103 for use in paraffin-embedded tissues will facilitate the distinction of HCL from other small B cell lymphomas in the nodal/extranodal setting.

show abstract

Section: Discussionmentioning

confidence: 99%

Morphological and immunophenotypical features of hairy cell leukaemia involving lymph nodes and extranodal tissues

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In two similar cases from the literature, Gray et al (2013) reported the case of a woman with hairy cell leukemia with complaints of lower back and hip pain, normal blood work, and unremarkable x-rays, whereas a second case by Pemmaraju et al (2015) reported a case of pathological fracture in a woman with breast cancer who experienced a fractured hip after trauma. A subsequent biopsy reported classical hairy cell leukemia.…”

Section: Lytic Bone Lesions In Hairy Cell Leukemiamentioning

confidence: 97%

“…A third of patients will develop an infection during the course of their disease, and overall prognosis has markedly improved (Damaj et al, 2009). In addition to infection, complications of hairy cell leukemia include autoimmune disorders and an increased risk of second malignancies (Grever, 2010;Pemmaraju, Gill, & Krause, 2015). Hairy cell leukemia is highly responsive to chemotherapy with first-line monotherapy with a purine nucleoside analog (pentostatin [Nipent ® ] or cladribine), which can induce response rates of 75%-90% (Greer et al, 2014).…”

Section: Clinical Highlightsmentioning

confidence: 99%

“…Lytic bone lesions are considered a rare and unusual finding in cases of hairy cell leukemia, particularly at the time of presentation, but may be present in about 3% of all patients (Pemmaraju et al, 2015). The most prominent site of skeletal involvement tends to be the proximal femur neck or head, but other less common bony sites include the skull, ribs, humerus, vertebrae, tibia, and fibulae (Filippi, Franco, Marinone, Tarella, & Ricardi, 2007).…”

Section: Lytic Bone Lesions In Hairy Cell Leukemiamentioning

confidence: 99%

See 1 more Smart Citation

Hairy Cell Leukemia and Bone Pain

Streu

2016

ONF

View full text Add to dashboard Cite

Hairy cell leukemia is a relatively rare but distinct B-cell lympho-proliferative disorder of the blood, bone marrow, and spleen that accounts for only 2% of all adult leukemia cases. The median age at presentation is 50-55 years, with a 4:1 male to female predominance. Although considered uncommon, a number of unusual clinical presentations have been noted in the literature, including the presence of peripheral lymphadenopathy, lytic bone lesions, skin involvement, organ involvement, and central nervous system involvement. Unlike the clinical management of other hematologic malignancies, no current system is used to stage hairy cell leukemia.

show abstract

“…28 Therapy with 2-CDA has been used in 10 of 36 (28%) HCL patients with bone involvement reported in English language publications since 1983 (Table 1). 19,20,23,27,29,30,33,36,49 In three patients, 2-CDA was combined with RT 27,28,34 and all achieved long-lasting response, including six CR (70%). Most patients with skeletal HCL have a high tumor burden with obvious bone marrow infiltration with HCL and should be treated with purine analogs.…”

Section: Treatmentmentioning

confidence: 99%

Bone lesions in hairy cell leukemia: Diagnosis and treatment

Robak

Jesionek-Kupnicka

Kupnicki

et al. 2020

European J of Haematology

View full text Add to dashboard Cite

Hairy cell leukemia (HCL) is a rare and indolent form of small mature B-cell leukemias. The annual incidence of HCL is estimated to be 0.3 cases per 100 000, and the disease comprises 2%-3% of all leukemias. 1,2 It was estimated that 1100 new cases of HCL and 4060 deaths occurred in 2016 in the USA. 3,4 It is mostly a disease of middle-aged males (median age 55 years and 4:1 male predominance). Patients present most frequently with splenomegaly, pancytopenia, and bone marrow infiltration. Hairy cells characteristically stain strongly positive for tartrate-resistant acid phosphatase (TRAP) and have a typical pattern of B-cell antigen expression (CD19, CD20) with co-expression of CD11c, CD25, and CD103. Cell surface markers associated with normal B-cell activation, especially CD22, CD72, and CD40, are also strongly expressed. 3,4 The BRAF V600E mutation is present in all patients and is regarded as a disease-defining genetic event. 5 Purine nucleoside analogs (PNA), cladribine (2-CDA), and pentostatin (DCF, deoxycoformycin) are the drugs of choice in first-line treatment of HCL 3,4 ; they induce durable and unmaintained complete response (CR) in more than 70% of patients, with relapse rates of 30%-40%, after 5-to 10-year follow-up. However, despite very high initial response rates, many patients ultimately relapse or develop refractory disease and will require novel therapies after these agents. 3 Unusual clinical manifestations of HCL are occasionally reported. 6-14 These rare symptoms may include bulky abdominal lymphadenopathy, tumor masses in the mediastinum, paravertebral masses,

show abstract

Hairy Cell Leukemia Presenting with a Lytic Bone Lesion

Cited by 4 publications

References 7 publications

Morphological and immunophenotypical features of hairy cell leukaemia involving lymph nodes and extranodal tissues

Morphological and immunophenotypical features of hairy cell leukaemia involving lymph nodes and extranodal tissues

Hairy Cell Leukemia and Bone Pain

Bone lesions in hairy cell leukemia: Diagnosis and treatment

Contact Info

Product

Resources

About